ANABV (ANABV)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-29

Key Insights

  • Director Susannah Gray received 11,250 restricted stock units (RSUs) on April 27, 2026, representing a standard equity compensation arrangement rather than insider buying activity.
  • The RSUs vest over approximately 3 years with 1/3 vesting on April 27, 2027 and the remaining 2/3 in equal annual installments, contingent on continued service to the company.
  • This is a routine equity grant to a board member with no market purchase involved (grant price of $0), indicating normal director compensation practices rather than a significant market signal about company prospects.
Filing tone (AI): Neutral
View Original Filing →
Insider Trading Filed: 2026-04-22

Key Insights

  • AnaptysBio completed a spin-off of First Tracks Biotherapeutics on April 20, 2026, distributing 100 shares of First Tracks common stock to AnaptysBio shareholders, representing a corporate restructuring event.
  • The reporting person is listed as AnaptysBio, Inc. (the parent company) rather than an individual insider, indicating this Form 4 documents the organizational transaction rather than a traditional insider trading activity.
  • After the spin-off, the beneficial ownership shown is 0 shares of First Tracks for AnaptysBio, suggesting complete divestiture of the subsidiary through the distribution to shareholders.
Filing tone (AI): Neutral
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new ANABV filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.